Suchergebnisse - "Itolizumab"

PubPharm (63)

41

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab

enthalten in: PloS one | 2017

von Bughani, U. | Saha, A. | Kuriakose, A. | +11

ErratumIn: PLoS One. 2018 Jan 30;13(1):e0192335. - PMID 29381749

42

Commentary : CD6 As a Potential Target for Treating Multiple Sclerosis

enthalten in: Frontiers in immunology | 2017

von Consuegra-Fernández, M. | Isamat, M. | Lozano, F.

CommentOn: Proc Natl Acad Sci U S A. 2017 Mar 7;114(10 ):2687-2692. - PMID 28209777

43

Commentary: CD6 As a Potential Target for Treating Multiple Sclerosis

in: Frontiers in Immunology | 2017

von Marta Consuegra-Fernández | Marcos Isamat | Francisco Lozano | +2

44

Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis

in: Case Reports in Dermatology | 2017

von Ganesh Pai | Anusha H. Pai

45

A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis

in: Indian Dermatology Online Journal | 2017

von Anchala Parthasaradhi | Vinay Singh | S G Parasramani | +4

46

Itolizumab in psoriasis

enthalten in: Indian journal of dermatology | 2017

von Srivastava, A.

47

Safety and Efficacy of Itolizumab in the Treatment of Psoriasis : A Case Series of 20 Patients

enthalten in: Journal of clinical and diagnostic research : JCDR | 2016

von Parthasaradhi, A.

48

Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody

enthalten in: Indian journal of dermatology, venereology and leprology | 2016

von Gupta, A. | Sharma, Y. | Deo, K. | +1

49

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis : safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study

enthalten in: Clinical rheumatology | 2016

von Chopra, A. | Chandrashekara, S. | Iyer, R. | +10

50

Immunological evaluation of rheumatoid arthritis patients treated with itolizumab

enthalten in: mAbs | 2016

von Aira, L. | Hernández, P. | Prada, D. | +6